| Literature DB >> 20096286 |
Tamás Csont1, Anikó Görbe, Erika Bereczki, Andrea Szunyog, Eda Aypar, Melinda E Tóth, Zoltán V Varga, Csaba Csonka, Ferenc Fülöp, Miklós Sántha, Péter Ferdinandy.
Abstract
Biglycan, a proteoglycan component of extracellular matrix, has been suspected to contribute to the development of atherosclerosis, but overexpression of biglycan in transgenic mice has been shown to induce cardioprotective genes including nitric oxide (NO) synthases in the heart. Therefore, here we hypothesized if exogenous administration of biglycan exerts cytoprotection. Primary cardiomyocytes from neonatal rats were subjected to 150 min hypoxia and 2 h reoxygenation. Mortality of cardiomyocytes was dose-dependently attenuated by pretreatment with 1-100 nM biglycan. Biglycan enhanced eNOS mRNA and protein, and significantly increased NO content of cardiomyocytes. The NO synthase inhibitor l-nitro-arginine-methyl-ester significantly attenuated the cytoprotective effect of biglycan. This is the first demonstration that biglycan leads to cytoprotection against hypoxia/reoxygenation injury, and that this phenomenon is partially mediated by an NO-dependent mechanism. Copyright (c) 2009 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20096286 DOI： 10.1016/j.yjmcc.2010.01.013
Source DB: PubMed Journal: J Mol Cell Cardiol ISSN： 0022-2828 Impact factor: 5.000